How Cochrane is responding to COVID-19 in 2021
In 2020, Cochrane ’s editorial response to COVID-19 pandemic brought together collaborations across our global organization to publish reviews addressing stakeholder needs as they emerged. Large, highly organized review teams worked together to produce evidence addressing priorities in treatment, prevention, and di agnostics. In 2021, Cochrane continues to produce new and updated reviews in response to the pandemic.In this interview with Deputy Editor in Chief Toby Lasserson and Executive Editor of Cochrane ' s Central Editorial Service Helen Wakeford, we ask them about Cochrane ’s editorial approach to COVID-19 in 2021. The interview supports their paper, which sets out how Cochrane will respond to COVID-19 going forward and the priorities which inform this response.What have you set out to explain inthis paper?Helen: " The scope of reviews that Cochrane could potentially publish on COVID-19 is enormous. In addition, most review questions have a rapidly evolving evidence base that demands frequent updating of the review in order for it to remain useful to readers. So we needed to prioritise key topics on which to focus our resources. This paper sets out those priorities, and the rationale for why we have identified them as such. In 2021 and beyond, we will consider future submissions against these priorities. We will also be able to identify evidence synthesis gaps within our priority areas and actively commission reviews.We are aware that the COVID-19 pandemic ...
Source: Cochrane News and Events - Category: Information Technology Authors: Lydia Parsonson Source Type: news
More News: 1918 Spanish Flu | Brain | COVID-19 | Epidemics | Epidemiology | Flu Pandemic | Influenza | Influenza Vaccine | Information Technology | International Medicine & Public Health | Laboratory Medicine | Men | Neurology | Outbreaks | Pandemics | PET Scan | Respiratory Medicine | Vaccines